For life sciences organizations working on treatments for European patients, developing and executing a go-to-market strategy can be challenging, time-consuming, and resource-intensive. From pre-clinical research through post-launch commercialization, focused use of real-world data throughout the product life cycle can help reveal critical insights needed to demonstrate the need for and value of treatments. Solid research and analytical strategy, in combination with robust European real-world data, can help organizations develop market-specific insights when pursuing European markets.
Through a collaboration with Cegedim Health Data, IBM® Watson Health® offers research solutions with anonymized, patient-level EHR data for nearly 60 million European patients from THIN®, A Cegedim database. By partnering with Watson Health, life sciences organizations can analyze European data within the self-service platform IBM MarketScan® Treatment Pathways or work with Watson Health researchers to design and conduct studies to generate insights across a variety of therapeutic areas.
This paper investigates the association of pertinent clinical factors with the risk of bone fractures in adult patients with type 2 diabetes mellitus using anonymized electronic medical record data from THIN®, A Cegedim Database.
Click here for more information on HEOR Services or IBM MarketScan Treatment Pathways.